Zentalis Pharmaceuticals, INC. (ZNTL) — SEC Filings

Overview

Zentalis Pharmaceuticals, INC. (ZNTL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 17, 2026: On April 17, 2026, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing updates on its clinical programs. The company presented data from its Phase 1 study of ZN-c3 in patients with advanced solid tumors, as well as data from its Phase 1/2 study of ZN-d5 in patients with solid tumors. These

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 42 neutral. The dominant filing sentiment for Zentalis Pharmaceuticals, INC. is neutral.

Filing Type Overview

Zentalis Pharmaceuticals, INC. (ZNTL) has filed 22 8-K, 2 10-K, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 1 8-K/A, 14 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (48)

• Zentalis Pharmaceuticals Presents Clinical Data Updates — 8-K · Apr 17, 2026 Risk: medium
  On April 17, 2026, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing updates on its clinical programs. The company presented data from its Phase 1 st
• 8-K Filing — 8-K · Apr 9, 2026
• Zentalis Bets Big on Azenosertib Amidst Mounting Losses — 10-K · Mar 26, 2026 Risk: high
  Zentalis Pharmaceuticals, Inc. (ZNTL) reported significant net losses for the fiscal year ended December 31, 2025, and expects these losses to continue as it ha
• Zentalis Pharmaceuticals Announces Board and Executive Changes — 8-K · Dec 15, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on December 15, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the comp
• Zentalis Narrows Q3 Loss Amidst R&D Cuts, Cash Position Improves — 10-Q · Nov 10, 2025 Risk: high
  Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $26.691 million for the three months ended September 30, 2025, a decrease from the $40.158 million
• Zentalis Pharmaceuticals Announces Board Changes and Filings — 8-K · Aug 26, 2025 Risk: medium
  On August 26, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the departure of Dr. Lori Friedman fr
• Zentalis Reports No Revenue, Focuses on Clinical Pipeline Advancement — 10-Q · Aug 6, 2025 Risk: high
  Zentalis Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as it remains a cli
• Zentalis Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 18, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 17, 2025. The filing details
• Zentalis Pharmaceuticals Files 8-K — 8-K · Jun 2, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on June 2, 2025, reporting events as of May 31, 2025. The filing primarily concerns Regulation FD disclosures and fi
• Zentalis Pharmaceuticals Files Proxy Statement Amendment — DEFA14A · May 23, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement (DEFA14A) on May 23, 2025. This filing concerns the compan
• Zentalis Pharmaceuticals Files 8-K — 8-K · May 20, 2025 Risk: low
  On May 20, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Stat
• Zentalis Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its busin
• Zentalis Pharma Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation and annual meeting information for the fiscal year ending Dec
• Zentalis Pharmaceuticals Files 8-K — 8-K · Apr 28, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on April 28, 2025, reporting on events as of April 27, 2025. The filing primarily concerns Regulation FD disclosures
• Zentalis Pharmaceuticals Files 2024 10-K — 10-K · Mar 26, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 2024 10-K on March 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceuti
• Zentalis Pharmaceuticals Files 8-K — 8-K · Mar 17, 2025 Risk: low
  On March 15, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhib
• Zentalis Pharmaceuticals Files 8-K Report — 8-K · Jan 29, 2025 Risk: low
  On January 29, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with fi
• Zentalis Sells Subsidiary, Focuses on Oncology Pipeline — 8-K · Jan 28, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on January 22, 2025, that it has entered into a definitive agreement to sell its Zentalis Pharmaceuticals, LLC subsidia
• Zentalis Pharmaceuticals Amends Director and Officer Filings — 8-K/A · Dec 19, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K/A on December 19, 2024, to amend a previous filing regarding changes in directors and officers, and compensatory arr
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Zentalis Pharma Appoints New Chief Medical Officer — 8-K · Nov 13, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on November 12, 2024, the appointment of Dr. Lori J. Rabin as Chief Medical Officer. Dr. Rabin brings extensive experie
• Zentalis Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its b
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G/A Filing — SC 13G/A · Oct 18, 2024
• SC 13G/A Filing — SC 13G/A · Oct 7, 2024
• Zentalis Pharmaceuticals Files 8-K Report — 8-K · Sep 16, 2024 Risk: low
  On September 16, 2024, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Other Events, along with
• Zentalis Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busine
• Zentalis Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Jun 21, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain spec
• 8-K Filing — 8-K · Jun 3, 2024
• Zentalis Pharma Appoints New CMO, Dr. Melissa Johnson — 8-K · May 29, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on May 24, 2024, the appointment of Dr. Melissa L. Johnson as Chief Medical Officer, effective immediately. Dr. Johnson
• Zentalis Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Zentalis Pharmaceuticals, Inc. filed a 10-Q report for the pe
• Zentalis Pharmaceuticals, Inc. DEF 14A Filing — DEF 14A · Apr 29, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Filing Type: DEF 14A. Reporting Period: 2024-06-21. File
• Zentalis Pharmaceuticals Appoints New CMO, Director — 8-K · Apr 11, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. announced on April 5, 2024, the appointment of Dr. Lori J. Rabin as Chief Medical Officer and the election of Ms. Karen L. Smith
• Zentalis Pharmaceuticals Files 8-K Report — 8-K · Apr 9, 2024 Risk: low
  On April 9, 2024, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibi
• Zentalis Pharma Files 8-K for Financial Results — 8-K · Feb 27, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, to report its Results of Operations and Financial Condition, including Financial Statements an
• Zentalis Pharmaceuticals Files 8-K on Bylaw Amendments, Fiscal Year Change — 8-K · Feb 15, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 12, 2024. The filing indicates amendments to its Ar
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Capital International Investors Amends Zentalis Pharma Stake — SC 13G/A · Feb 9, 2024 Risk: low
  Capital International Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of Zental
• FMR LLC & Abigail Johnson Maintain 14.6% Stake in Zentalis Pharma — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have filed an amendment to their SC 13G, indicating they collectively beneficiall
• Wellington Management Trims Zentalis Pharma Stake to 7.0% — SC 13G/A · Feb 9, 2024 Risk: medium
  Wellington Management Group LLP, a major investment firm, filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of Zentalis Phar
• BlackRock Amends Zentalis Pharma Stake, Signals Continued Confidence — SC 13G/A · Jan 29, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating a change in its ownership of Zentalis Pharmaceuticals, Inc. common stock as of December
• Zentalis Pharma 8-K: Listing, Officer Changes Reported — 8-K · Jan 25, 2024
  Zentalis Pharmaceuticals, Inc. filed an 8-K on January 25, 2024, reporting events from January 19, 2024. The filing indicates potential issues with continued li
• State Street Corp. Amends Zentalis Pharma Stake Filing — SC 13G/A · Jan 25, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Zentalis Pharmaceuticals Inc
• Zentalis Pharma Files Routine 8-K, Updates Admin Info — 8-K · Jan 8, 2024
  Zentalis Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024. This filing is a routine current report, pr

Frequently Asked Questions